After 12 weeks, the study doctor decided if a patient could be given up to three more
re-treatments with botulinum toxin type A (400 units). All the patients knew that they
received botulinum toxin type A (400 units). This is called the open-label phase.
Which patients were included in this study?
Studies have a list of requirements for patients who can enrol (inclusion criteria) and
those who can’t (exclusion criteria). For this study, the main inclusion and exclusion
criteria are listed below.
Men and women with upper limb spasticity were included in the study if they:
• Were between 20 and 80 years old.
• Had a stroke at least three months before starting the study.
• Were treated with botulinum toxin type A (240 units) for upper limb
spasticity at least 16 weeks before starting the study.
• Had severe symptoms which may benefit from treatment with the
higher dose of botulinum toxin type A (400 units).
• Had symptoms of spasticity in the muscles of finger, thumb, wrist, and
elbow.
• Had no lung-related problems at the start of the study.
Men and women were excluded from the study if they had:
• Upper limb spasticity caused by an injury or disease other than stroke.
• Been treated for spasticity in the non-paralysed upper limb.
• Permanent shortening and hardening of any finger, wrist, elbow, or,
shoulder muscle.
• Severe swelling and/or pain or slight dislocation in the joints of any
finger, wrist, elbow, or, shoulder.
• Any conditions or taken any medicines that could affect the results of
the study.